Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue

DOI: 10.1007/s00240-003-0360-z
Urological Research, 2004, 32, 317-22.

#	Paper	IF	Citations
34	Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. *Journal of Immunotherapy*, **2005**, 28, 79-119	5	27
33	Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. *Clinical and Experimental Immunology*, **2006**, 146, 518-23	6.2	26
32	TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. *Journal of Bone and Mineral Research*, **2007**, 22, 37-44	6.3	51
31	Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. *Cancer Investigation*, **2006**, 24, 640-56	2.1	7
30	Genomics of renal cell cancer: the biology behind and the therapy ahead. *Clinical Cancer Research*, **2007**, 13, 685s-692s	12.9	36
29	The Importance of Pathology and Genetics for the Diagnosis and Therapy of Renal Cell Carcinoma. *European Urology Supplements*, **2007**, 6, 603-610	0.9	3
28	Immune suppression in renal cell carcinoma. *Seminars in Cancer Biology*, **2007**, 17, 330-43	12.7	34
27	Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma. *Journal of Cancer Research and Clinical Oncology*, **2007**, 133, 487-92	4.9	6
26	Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells. *Clinical Cancer Research*, **2010**, 16, 164-73	12.9	33
25	The immunoregulatory mechanisms of carcinoma for its survival and development. *Journal of Experimental and Clinical Cancer Research*, **2011**, 30, 12	12.8	41
24	The notch and TGF- signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. *PLoS ONE*, **2011**, 6, e23057	3.7	47
23	Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition. *Human Pathology*, **2012**, 43, 708-19	3.7	36
22	The additional value of TGF 1 and IL-7 to predict the course of prostate cancer progression. *Cancer Immunology, Immunotherapy*, **2012**, 61, 905-10	7.4	24
21	Smad3 is the key to transforming growth factor- 1-induced osteoclast differentiation in giant cell tumor of bone. *Medical Oncology*, **2013**, 30, 606	3.7	12
20	Effects of TGF- signaling in clear cell renal cell carcinoma cells. *Biochemical and Biophysical Research Communications*, **2013**, 435, 126-33	3.4	27
19	LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC. *Molecular Cancer Research*, **2014**, 12, 1807-17	6.6	29
18	TGF- 1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. *Biological Research*, **2015**, 48, 26	7.6	27

17	miR-629 Targets TRIM33 to Promote TGF/Smad Signaling and Metastatic Phenotypes in ccRCC. *Molecular Cancer Research*, **2015**, 13, 565-74	6.6	53
16	Dysregulation of TGF Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. *Journal of Clinical Medicine*, **2016**, 5,	5.1	28
15	Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer. *Journal of Urology*, **2016**, 195, 1892-902	2.5	63
14	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. *Scientific Reports*, **2017**, 7, 41371	4.9	2
13	MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma. *Oxidative Medicine and Cellular Longevity*, **2017**, 2017, 3269379	6.7	27
12	A New Switch for TGF In Cancer. *Cancer Research*, **2019**, 79, 3797-3805	10.1	46
11	TGF- and microRNA Interplay in Genitourinary Cancers. *Cells*, **2019**, 8,	7.9	9
10	Epithelial to Mesenchymal Transition. **2021**,		1
9	Up-regulation of pVHL along with down-regulation of HIF-1 by NDRG2 expression attenuates proliferation and invasion in renal cancer cells. *PLoS ONE*, **2013**, 8, e84127	3.7	7
8	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. *PLoS ONE*, **2014**, 10, e0103258	3.7	18
7	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. *PLoS ONE*, **2016**, 11, e0165718	3.7	23
6	Targeting the TGF pathway in uterine carcinosarcoma. *Cell Stress*, **2020**, 4, 252-260	5.5	5
5	Differential expression of CD44 and CD24 markers discriminates the epitheliod from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells. *Oncotarget*, **2017**, 8, 15593-15609	3.3	6
4	Renal cell tumors convert natural killer cells to a proangiogenic phenotype. *Oncotarget*, **2020**, 11, 2571-2585	3.3	8
3	Anti-proliferative effect of honokiol on SW620 cells through upregulating BMP7 expression via the TGF-1/p53 signaling pathway. *Oncology Reports*, **2020**, 44, 2093-2107	3.5	2
2	A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma. *BMC Medical Genomics*, **2020**, 13, 190	3.7	0
1	Inflammatory Networks in Renal Cell Carcinoma. **2023**, 15, 2212		0